RCUS Arcus Biosciences, Inc.
USHealthcareAs of 2026-08-24
Why RCUS matters now
Arcus Biosciences, Inc. (RCUS) is a US stock in Healthcare. The latest InvestLog snapshot shows $30.15 with -0.63% on the session and $3.79B in market capitalization; recent performance reads 1-month +6.86% and YTD +2.01%.
The latest financial table shown here is Q1 2026, with revenue of $17.0M, net income of $-128.0M, and EPS of $-1.02. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -20.0%.
The latest indexable market news headline is "Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $28.00; recent insider activity includes PERLMAN ANDREW J filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.82
P/S
10.37
EV/EBITDA
-7.15
DCF Value
$-38.89
FCF Yield
-20.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.0%
Operating Margin
-168.6%
Net Margin
-156.4%
ROE
-69.0%
ROA
-37.0%
ROIC
-49.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.0M | $-128.0M | $-1.02 |
| Q4 2025 | $33.0M | $-98.0M | $-0.92 |
| FY 2025 | $247.0M | $-353.0M | $-3.29 |
| Q3 2025 | $26.0M | $-135.0M | $-1.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$31.00
Target (Median)
$28.00
Target Range
$22.00 - $47.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another key asset is Domvanalimab, an anti-TIGIT monoclonal antibody, undergoing Phase 2 development for first-line metastatic non-small cell lung cancer when administered with Zimberelimab. The company is also developing Quemliclustat, a small-molecule CD73 inhibitor, in Phase 1/1b studies for the initial treatment of metastatic pancreatic cancer. AB521, an oral small molecule HIF-2a inhibitor, is in Phase 1 trials for patients with von Hippel-Lindau disease. Arcus actively collaborates with other entities to advance its programs. It has a clinical development partnership with Strata Oncology, Inc. to assess Zimberelimab. Furthermore, a significant collaboration with AstraZeneca and BVF Partners L.P. is underway for a registrational Phase 3 clinical trial, testing Domvanalimab (an experimental anti-TIGIT antibody) alongside Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer. Additionally, Arcus holds licensing agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics for the development of an anti-CD39 antibody targeting various cancers. Incorporated in 2015, the company's corporate headquarters are located in Hayward, California.